At a glance

ClinicalIndex Comparison Record

Phase 1Completed· 13 enrolled

Drug / intervention

BIA 2-093 +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02287415

NCT02287415Phase 1Completed

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin in Healthy Volunteers

Bial - Portela C S.A.·interventional·Posted Nov 10, 2014·Updated Dec 1, 2014

In Brief

A Phase 1 clinical trial evaluating BIA 2-093 and Warfarin for Epilepsy. Completed, enrolled 13 participants.

Multiple-dose, open-label, single-period study consisting of three consecutive phases

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsEpilepsy

Countries--

Collaborators--

Phase 1CompletedFinished

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartMay 2002

Primary CompletionJul 2002

First PostedNov 2014

TodayJul 2026

First PostedNov 10, 2014

Enrollment StartMay 1, 2002

Primary CompletionJul 1, 2002

TodayJul 2, 2026

Enrollment to primary: 2 monthsPosted 11.6 years ago

BIA 2-093drug

Warfarindrug